Skip to Content

Type 2 Diabetes Linked to Decline in Verbal Memory, Fluency in Older Adults

FRIDAY, Dec. 14, 2018 -- Type 2 diabetes is associated with declines in verbal memory and fluency among older community-dwelling adults, according to a study published online Dec. 13 in Diabetologia.

Michele L. Callisaya, Ph.D., from the University of Tasmania in Australia, and colleagues examined the correlation between type 2 diabetes with brain atrophy and cognitive decline. A total of 705 participants without dementia (348 with diabetes and 357 without diabetes), aged 55 to 90 years, underwent brain magnetic resonance imaging (MRI) and neuropsychological measures at three time points during 4.6 years. Adjusting for covariates, the authors assessed longitudinal associations of type 2 diabetes with cognitive and MRI measures.

The researchers observed significant interactions between diabetes and time for verbal memory and verbal fluency (β, −0.06 and β, −0.03, respectively) after adjustment for age, sex, education, and vascular risk factors. At baseline, individuals with diabetes had lower brain and greater ventricular volumes (β, −14.273 and β, 2.672, respectively); however, researchers found no evidence that brain atrophy occurred at a greater rate over time or mediated the diabetes-cognition relationship.

"The effects of type 2 diabetes and poor metabolic health at midlife, and the impact of accrual of cerebrovascular lesions at older age, both deserve further study to inform preventative efforts against dementia," the authors write.

One author disclosed financial ties to the pharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)

© 2020 HealthDay. All rights reserved.

Posted: December 2018

Read this next

Green Tea, Coffee Intake Linked to Reduced Mortality in T2DM

THURSDAY, Oct. 22, 2020 -- For patients with type 2 diabetes, consumption of green tea and coffee is associated with reduced all-cause mortality, according to a study published...

Ertugliflozin Noninferior for CV Outcomes in T2DM With ASCVD

THURSDAY, Oct. 15, 2020 -- Ertugliflozin is noninferior to placebo with respect to major adverse cardiovascular events among patients with type 2 diabetes and atherosclerotic...

Sitagliptin May Cut Mortality in T2DM Patients With COVID-19

WEDNESDAY, Oct. 14, 2020 -- Sitagliptin treatment added to standard care is associated with reduced mortality and improved clinical outcomes for patients with type 2 diabetes...